- Gilead’s stock fell 4% on Monday after a coronavirus drug trial showed mixed results in moderately ill people.
- The company tested the drug in patients who received the treatment for both 5 days and 10 days.
- Patients who received it for 5 days were 65% more likely to show signs of recovery than those who received normal care, but the drug had limited benefits for the 10-day group.
- Remdesivir has been authorised for emergency use by the US Food and Drug Administration.
- Track the price of Gilead Sciences live on Markets Insider.
- Visit Business Insider’s homepage for more stories.
Shares in Gilead Sciences slipped 4% on Monday after a late-stage coronavirus drug trial showed that remdesivir had limited success treating moderately ill patients.
The company said that remdesivir helped patients in the trial with “moderate” disease recover more quickly when they took it for five days but it had limited benefits for patients who took it for 10 days.
Gilead said patients in the group that received remdesivir for five days were 65% more likely to show signs of clinical improvement compared to those who got usual care, without receiving the drug.
Remdesivir has been tested as a treatment for patients with COVID-19. It has been authorised for emergency use by the US Food and Drug Administration (FDA) and has been approved for use in Japan.
While Monday’s results affirm that remdesivir does have some success in treating COVID-19 it may raise questions how beneficial it will be overall.
Earlier test results in April showed hospitalized, severely ill COVID-19 patients recovered 31% faster when taking remdesivir instead of a placebo, according to results released by the US National Institutes of Health.
Gilead Sciences said in a statement: “We now have three randomised, controlled clinical trials demonstrating that remdesivir improved clinical outcomes by several different measures.”
“Today’s results showed that when treating moderate disease, a five-day course of remdesivir led to greater clinical improvement than standard care, adding further evidence of remdesivir’s benefit to previously released study results.”
Read more: Famed economist David Rosenberg says investors are falling into a classic market trap that’s historically preceded a further meltdown – and warns ‘there’s not going to be much of a recovery’
Gilead’s share price is up about 15% since the beginning of 2020.